Supplier News: Samsung Biologics, Cytiva, Aragen & More
The latest from CDMOs, CMOs, and suppliers featuring Samsung Biologics, Cytiva, Aragen, BioDuro, Kindeva, Alcami, Cellular Origins and Touchlight.
Chemicals/Chemical API Manufacturing
* BioDuro Opens Peptide Mfg Lab
Biologics Manufacturing
* Samsung Biologics Provides Update on Biomanufacturing, ADC & Drug Product Expansions
* Cytiva, Cellular Origins In Cell Therapy Mfg Pact
* Touchlight’s Synthetic DNA Mfg Facility Gets UK OK
Formulation Development/Drug Product Manufacturing
* Aragen Receives $100-M Investment from Quadria Capital
* Kindeva Receives $129-M US Gov’t Contract for Autoinjectors
General
* Alcami Names Interim CEO
Chemicals/Chemical API Manufacturing
BioDuro Opens Peptide Mfg Lab
BioDuro, an Irving, California-based CDMO of small and large molecules, has opened a fully-automated solid-phase peptide synthesis scale-up laboratory in Shanghai Zhangjiang High-tech Park in China.
The kilogram-scale peptide laboratory is equipped with automated solid-phase peptide synthesizers, cleavage systems, and freeze-drying equipment to support peptide synthesis scale-up to 800 mmol. It is designed to produce a wide range of peptide molecules, including linear peptides, cyclic peptides, and various peptide drug conjugates.
Source: BioDuro
Biologics Manufacturing
Samsung Biologics Provides Update on Biomanufacturing, ADC & Drug Product Expansions
Samsung Biologics has provided an update on several key expansions. The company announced that it plans to open it Bio Campus II in Songdo, Incheon, South Korea, this year (2025), with the first plant of the new site, Plant 5 (fifth biomanufacturing plant in the company’s overall network), slated to be operational in April 2025, which would bring the company’s total capacity to 784,000 liters. The company says it is also considering the construction of a sixth plant to proactively respond to the increasing demand for biologics which will increase its total production capacity to 964,000 liters, upon company board approval. Bio Campus II follows the company’s Bio Campus I, a manufacturing campus featuring four biomanufacturing plants
Additionally, Samsung Biologics has commenced antibody drug conjugate (ADC) services at its new dedicated facility in Songdo, Incheon, South Korea. Samsung Biologics recently expanded its collaboration with LigaChem Biosciences to support a series of its ADC programs at Samsung Biologics’ new dedicated ADC facility.
The company is also investing in pre-filled syringe (PFS)capabilities. The company’s fully automated PFS drug product line is slated to be cGMP ready by 2027.
Source: Samsung Biologics
Cytiva, Cellular Origins In Cell Therapy Mfg Pact
Cytiva and Cellular Origins, a Melbourn, UK-based cell & gene-therapy technology company, have entered an agreement for the manufacture of cell therapies. The companies plan to combine Cytiva’s automated Sefia platform with Cellular Origin’s automated robotic platform, Constellation, to increase the efficiency by which cell & gene-therapy manufacturers will be able to automate the manufacturing process.
Source: Cytiva
Touchlight’s Synthetic DNA Mfg Facility Gets UK OK
Touchlight, a London-based CDMO of synthetic DNA, has announced that its synthetic DNA manufacturing facility in Hampton, UK, has received GMP certification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Specifically, Touchlight has received a Manufacturer’s Authorization for Investigational Medicinal Products license from the MHRA for the GMP production of investigational API and critical starting materials in advanced therapy medicinal products from its manufacturing facility.
Source: Touchlight
Formulation Development/Drug Product Manufacturing
Aragen Receives $100-M Investment from Quadria Capital
Aragen, a CDMO of drug substanced and drug products, has secured a $100-million investment from Quadria Capital, an Asia healthcare-focused private equity firm. The investment will result in Quadria acquiring a minority stake in Aragen, by which Quandria values the overall company at approximately $1.4 billion. This funding will support Aragen’s strategic expansion of its capabilities and infrastructure in the US and Europe.
Source: Aragen and Quandria Capital
Kindeva Receives $129-M US Gov’t Contract for Autoinjectors
Kindeva Drug Delivery, a CDMO for sterile injectable, pulmonary, nasal, transdermal, and intradermal finished dosage products, has secured a contract, valued at up to $129 million, to supply DuoDote, a chemical nerve agent antidote autoinjector, to the US government for the Strategic National Stockpile, managed by the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.
DuoDote is an FDA-approved dual-chamber autoinjector, containing atropine and pralidoxime chloride, and is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides. The DuoDote autoinjectors will be manufactured and distributed from Kindeva’s fill–finish facility in St. Louis, Missouri.
Source: Kindeva Drug Delivery
General
Alcami Names Interim CEO
Alcami Corporation, a CDMO of drug products and provider of analytical testing services, has announced that Alcami’s Board Chair and former Chief Executive Officer (CEO), Patrick Walsh, will serve as Interim CEO, following the resignation of Bill Humphries as CEO. Walsh served as CEO of Alcami on two previous occasions and has served as Chairman over the last four years. In addition to his duties at Alcami, he currently serves as Chairman of ANI Pharmaceuticals, a bio/pharmaceutical company, Chairman of MedPharm, a CDMO of topical and transepithelial products, and is an Operating Partner at Ampersand Capital Partners.
Source: Alcami
